Engineered immune cells take on Hard-to-Treat prostate cancer
NCT ID NCT06046040
First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 26 times
Summary
This early-phase study tests a new treatment called TmPSMA-02 for men with metastatic castrate-resistant prostate cancer (mCRPC) that has not responded to standard therapies. The treatment uses the patient's own immune cells, modified to better recognize and attack cancer cells. The main goals are to check safety and find the right dose, with 30 participants expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Abramson Cancer Center of the University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.